Release
📈 Stocks
Palatin Technologies Unveils Preclinical Data for MC4R Agonist PL2001
(just now)
Palatin Technologies showcased preclinical results for its MC4R-selective peptide programs, highlighting PL2001's potential for once-weekly dosing and reduced side effects, with human…